Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life

• Published in: Cancer 1987-05, Vol.59 (10), p.1713-1716
• Main Authors: Presant, Cary A., Soloway, Mark S., Klioze, Sol S., Yakabow, Alun, Presant, Seth N., Mendez, Rafael G., Kennedy, Peter S., Wyres, Melody R., Naessig, Virginia L., Todd, Barbara, Wiseman, Charles L., Bouzaglou, Armand, Tanenbaum, Barton, Eventov, Daniel
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Aged; Antineoplastic agents; Biological and medical sciences; Buserelin - therapeutic use; Chemotherapy; Follow-Up Studies; Humans; Male; Medical sciences; Pharmacology. Drug treatments; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Quality of Life
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8

The safety and efficacy of buserelin, a luteinizing hormone‐releasing hormone (LH‐RH) agonist, was tested in 33 evaluable patients with Stages C or D adenocarcinoma of the prostate. With a minimum follow‐up duration of 10 months, there was one complete response and 22 partial responses (69%) by National Prostatic Cancer Project criteria, with a median duration greater than 18 months. Six patients (18%) had stable disease, median duration greater than 25 months, and only 12 patients have progressed. Performance status improved in 67%, patient‐scored pain improved in 75%, and quality of life improved in 58%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. Buserelin produces a high frequency of durable objective and subjective responses in patients with advanced prostatic carcinoma.